Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSE 2.0 vs Liraglutide for Obesity
NCT05705388Recruiting
- Sponsor
- Emirates Health Services
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of liraglutide in obesity (2 arms), sponsored by Emirates Health Services. Primary endpoints: Total Body Weight Loss at 6 months, Percentage of subjects with >=5 percent total body weight loss at 6 months and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05705388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05705388.